Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

ImmVira Posts Positive Data from Trial of Oncolytic Virus Injection for Melanoma

publication date: Feb 9, 2023

Shenzhen ImmVira reported its first intratumoral injected oncolytic virus product, MVR-T3011 IT, was effective in early tests, raising Progression-Free Survival in melanoma patients to 12.9 months. The patients had previously failed another treatment. MVR-T3011 is a 3-in-1 oncolytic herpes simplex virus that aims to achieve the best profile of attenuated HSV-1 with high levels of replication in tumor cells while causing only highly restricted replication in normal cells. The product includes two well-validated exogenous genes, PD-1 antibody and IL-12, to enhance the immune responses in the tumor microenvironment. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital